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Abstract: Visceral adipose tissue (VAT) inflammation and metabolic dysregulation are key
components of obesity-induced metabolic disease. Upregulated arginase, a ureahydrolase enzyme
with two isoforms (A1-cytosolic and A2-mitochondrial), is implicated in pathologies associated
with obesity and diabetes. This study examined A2 involvement in obesity-associated metabolic
and vascular disorders. WT and globally deleted A2(−/−) or A1(+/−) mice were fed either a high
fat/high sucrose (HFHS) diet or normal diet (ND) for 16 weeks. Increases in body and VAT weight of
HFHS-fed WT mice were abrogated in A2−/−, but not A1+/−, mice. Additionally, A2−/− HFHS-fed
mice exhibited higher energy expenditure, lower blood glucose, and insulin levels compared to
WT HFHS mice. VAT and adipocytes from WT HFHS fed mice showed greater A2 expression and
adipocyte size and reduced expression of PGC-1α, PPAR-γ, and adiponectin. A2 deletion blunted
these effects, increased levels of active AMPK-α, and upregulated genes involved in fatty acid
metabolism. A2 deletion prevented HFHS-induced VAT collagen deposition and inflammation,
which are involved in adipocyte metabolic dysfunction. Endothelium-dependent vasorelaxation,
impaired by HFHS diet, was significantly preserved in A2−/−mice, but more prominently maintained
in A1+/− mice. In summary, A2 is critically involved in HFHS-induced VAT inflammation and
metabolic dysfunction.
Keywords: arginase; obesity; inflammation; metabolism; endothelial dysfunction; fatty acid
oxidation; AMPK-α
1. Introduction
Obesity, particularly central obesity, is associated with chronic inflammation and is considered
to be a key contributor to metabolic dysfunctions. It is also an independent risk factor for all-cause
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mortality, and is an especially high-risk factor for cardiovascular diseases [1–4]. Obesity is a state
of excess nutrients that exceed the buffering capacity of adipocytes, the main component of adipose
tissue [5]. Adipocytes thus become larger, hypoxic, and insulin resistant which results in hyperglycemia
and pathological ectopic fat deposition [6].
These adipocytes also become senescent and undergo apoptosis, inducing a strong inflammatory
response and fibrosis [7,8]. In addition, during obesity, adipocytes have an altered adipokine secretion
profile in which pro-inflammatory adipokines are elevated and anti-inflammatory adipokines, such
as adiponectin, are reduced further exacerbating this deleterious environment. These compounding
effects lead to chronic inflammation, insulin resistance, and development of cardiovascular disease [9].
A possible strategy to reduce adiposity is to increase energy expenditure by inducing mitochondrial
biogenesis and activating fatty acid oxidation in the visceral adipose tissue (VAT) [10]. This can
be achieved by activating 5′ adenosine monophosphate-activated protein kinase-α (AMPK-α), the
central regulator of energy homeostasis that promotes energy conservation and induces fatty acid
β-oxidation [11].
Here we report on studies showing the involvement of the mitochondrial isoform of the
arginase enzyme, arginase 2 (A2) in visceral adiposity and the associated inflammation and metabolic
dysfunction. Arginase is a ubiquitous enzyme that has two isoforms, cytosolic A1 and mitochondrial
A2 [12]. We, and others, have shown that increased arginase expression is involved in cardiovascular
disease states in humans and animal models by competing with nitric oxide synthase (NOS) for their
common substrate, L-arginine and limiting synthesis of nitric oxide (NO) [12–14]. Recent studies in
animal models of diet-induced or genetic obesity also have shown that increased arginase expression
is involved in vascular and adipose tissue inflammation [15,16]. Our laboratory recently demonstrated
that mice challenged with a high fat/high sucrose diet (HFHS) were protected against obesity-induced
vascular endothelial dysfunction and adipose tissue inflammation by the deletion of A1 in endothelial
cells or by chronic treatment with an arginase inhibitor. This protection was associated with preserved
levels of NO and reduced oxidative stress [17,18].
Previous studies have shown that the global deletion of A2 protects against age-associated
pancreatic β-cell apoptosis and obesity-induced atherosclerosis and insulin resistance [19,20]. However,
the precise role of A2 in systemic metabolic activity and adipocyte lipid metabolism during obese
conditions remains unknown. In addition, the effect of A2 on the macrophage inflammatory response is
controversial [16,21,22]. In this study, we examined the specific metabolic consequences of A2 deletion
in a mouse model of obesity and investigated the underlying mechanisms behind these observations,
as well as the role of A2 expression in the macrophage polarization phenotype in adipose tissue.
2. Results
2.1. A2 Deletion Prevents High Fat/High Sucrose (HFHS) Diet-Induced Obesity
Wild type (WT) male mice fed the HFHS diet for 16 weeks showed significant increases in body
weight and total adiposity, as determined through nuclear magnetic resonance (NMR) analysis of
the percentage of fat mass/body weight (Figure 1A,B, respectively). These increases in body weight
and fat mass were largely prevented in the A2−/− mice. The relative amount of VAT weight to body
weight was also significantly increased in the WT mice fed the HFHS diet (Figure 1C). This alteration
also was significantly attenuated in the A2−/− mice. There were no differences in weight gain, fat
mass percentage, or visceral adiposity between WT and A2−/− mice fed the normal chow diet (ND).
A2−/− HFHS-fed mice also showed significantly lower levels of fasting blood glucose and
postprandial serum insulin when compared to WT HFHS-fed mice (Figure 1D,E, respectively). These
results raised questions about the possible effect of A2 deletion on lipid accumulation in the liver or
adipogenic differentiation. As shown in Figure 1F, liver sections from the WT HFHS group exhibited
increased lipid deposits in the form of small vacuoles. This was ameliorated in the A2−/− group.
Additionally, there was no effect of A2 deletion on adipogenic differentiation as determined by Oil
Int. J. Mol. Sci. 2019, 20, 1462 3 of 21
Red O staining for lipid accumulation in in vitro differentiated preadipocytes isolated from the stromal
vascular fraction (SVF) of VAT (Figure 1G,H and Supplementary Figure S1).Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 3 of 22 
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< 0.05 when compared to WT on the same diet. Representative photomicrographs of hemotoxylin and 103 
eosin-stained liver tissue sections from WT and A2−/− after 16 weeks on HFHS or ND (F), scale bar = 104 
50 μM. Representative images of cytoplasmic lipid droplets in preadipocytes from SVF of VAT of WT 105 
and A2−/− mice stained with Oil Red O after eight days of in vitro differentiation (G) and the 106 
corresponding quantification (H), n = 3 per group). 107 
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metabolic rates than WT HFHS mice, as evidenced by an increase in both O2 consumption (VO2) 113 
(Figure 2A–C) and CO2 release (VCO2) (Figure 2D–F) during both day/light and night/dark. The WT 114 
mice fed HFHS exhibited a significantly lower respiratory exchange ratio (VCO2/VO2) (Figure 2G–I) 115 
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the proportional increases in VO2 and VCO2 observed with A2−/− HFHS mice compared to WT, there 117 
was no significant difference between WT and A2−/− mice in the respiratory exchange ratio during 118 
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Figure 1. A2 deletion attenuates HFHS di t-i ced increases in body weight, adiposity, VAT
expansion, fasting blood glucose, postprandial insulin, and l pid acc mulation in th liver
without affecting adipocyte differentiation. Growth curves (A), n = 8–17 per group; percentage of body
fat mass measured by nuclear magnetic resonance spectroscopy (B), n = 5–9 per group; percentage of
VAT weight relative to body weight (C), n = 8–14 per group; fasting blood glucose (D) and fed serum
insulin (E), n = 5–8 mice per group are shown for WT and A2−/− mice. Values are represented as mean
± SEM. * P < 0.05 when compared to ND-fed mice within the same genotype, # P < 0.05 when compared
to WT on the same diet. Representative photomicrographs of hemotoxylin and eosin-stained liver tissue
sections from WT and A2−/− after 16 weeks on HFHS or ND (F), scale bar = 50 µM. Representative
images of cytoplasmic lipid droplets in preadipocytes from SVF of VAT of WT and A2−/− mice stained
with Oil Red O after eight days of in vitro differentiation (G) and the corresponding quantification (H),
n = 3 per group).
2.2. A2 Deletion Ameliorates the HFHS Diet-Induced Decrease in Metabolic Rate and Energy Expenditure
To understand how A2 deletion contributes to metabolic activity and the leaner phenotype,
metabolic cage studies were performed. Examination of quantity of food consumed (Suppl mentary
Figure S2A) a d locomotor activity (Supplementary Figure S2B) revealed that there were no significant
differences among all the groups. However, the A2−/− HFHS mice exhibited higher metabolic rates
than WT HFHS mice, as evidenced by an increase in both O2 consumption (VO2) (Figure 2A–C) and
CO2 release (VCO2) (Figure 2D–F) during both day/light and night/dark. The WT mice fed HFHS
exhibited a significantly lower respiratory exchange ratio (VCO2/VO2) (Figure 2G–I) compared to
those on ND, indicating their transition from carbohydrate to lipid metabolism. Due to the proportional
increases in VO2 and VCO2 observed with A2−/− HFHS mice compared to WT, there was no significant
differenc between WT and A2−/− mice in the respiratory exchan e ratio uring d y (Fig r 2G,H)
or night (Figure 2G,I), which indica s that A2 deletion has n effect on fu l preference. Interestingly,
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the HFHS diet-induced decrease in energy expenditure (heat produced) exhibited in WT mice was
prevented by A2 deletion, during both day (Figure 2J,K) and night (Figure 2J,L). This effect could be
attributed to the higher rates of fatty acid oxidation observed with the HFHS diet in A2−/− versus WT
mice (Figure 2M,N).
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Figure 2. A2 deletion improves whole b dy metabolism. Oxygen consumption (VO2) (A–C) and carbon
dioxide pro uce (VCO2) (D–F), represented as mL/kg/h; respiratory exchange r tio calculated
as VCO2/VO2 (G–I) and energy expenditure (J–L) calculated as kcal of heat produced/h/body
weight, fatty acid oxidation rate calculated as kcal/h during light and dark cycles (M,N). Values
are means ± SEM; n = 5–9 mice/group. * P < 0.05 when compared to ND-fed mice within the same
genotype, # P < 0.05 when compared to WT on the same diet.
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2.3. A2 Deletion Protected against HFHS Diet-Induced Adipocyte Hypertrophy and VAT Fibrosis
We also examined the effects of A2 deletion on HFHS diet-induced adipocyte expansion and
fibrosis of the extracellular matrix. Analysis of extracellular matrix fibrosis/collagen deposition by
Masson’s trichrome staining showed a marked increase in collagen fibers (blue stain) in the VAT from
the HFHS mice compared to the ND controls (Figure 3A). The A2 deletion completely blocked this
HFHS-induced extracellular matrix fibrosis, as indicated by less blue staining compared to the VAT
samples from WT mice on the HFHS diet (Figure 3B). Morphometric analysis of the adipocytes showed
a significant increase in the size of the cells in the WT HFHS group compared to the ND control.
This HFHS diet-induced hypertrophy was attenuated in the A2−/− mice (Figure 3C).
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Figure 3. A2 deletion limits HFHS-induced VAT fibrosis and adipocyte hypertrophy. Representative
photomicrographs of VAT show Masson’s trichrome staining of collagen/fibrosis depicted in blue
color (A), Scale bar = 20 µM and quantified as % of trichrome positive area to total VAT area (B).
Quantification of HFHS diet-induced increases in adipocyte area is shown for WT and A2−/− mice (C).
Data are presented as mean ± SEM, n = 3–5 mice/group. * P < 0.05 when compared to ND-fed mice
within the same genotype, # P < 0.05 when compared to WT on the same diet.
2.4. A2 Deletion Protected against HFHS Diet-Induced Pro-Inflammatory Macrophage Infiltration in the VAT
Inflammation is a late-stage consequence of pathological expansion and fibrosis of the VAT. Flow
cytometric analysis of the VAT SVF showed over a 3-fold increase in macrophage infiltration in the
VAT of the WT HFHS mice compared to ND mice (Figure 4A,B); an effect that was prevented in the
A2−/− ani als. To determine the phenotype of the infiltrating macrophages, we used antibodies
against the integrin CD11c, which is abundant in pro-inflammatory M1-like macro hages, and
t e mannose receptor CD206, which is abundant in a ti-inflammatory M2-like macrophages [18].
The HFHS diet treatment resulted in a marked elevation in the number of pro-inflammatory M1-like
infiltrating macrophages, which was abolished in the A2−/− mice (Figure 4A,C). Interestingly, t e
A2−/− mice fed the ND showed a significantly higher percentage of CD206-positive anti-inflammatory
macrophages com ared to the WT ND group (Figure 4A,D). Consistent with the lack of an increase
in pro-inflammatory macrophage in the A2−/− VAT after HFHS feeding, mRNA expression of the
pro-inflammatory cytokine, tumor necrosis factor (TNF)-α, and chemokine, monocyte chemoattractant
protein-1 (MCP-1) were lower in adipocytes from A2−/− mice compared to those from WT mice
(Figure 4E,F, respectively).
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Figure 4. A2 deletion limits HFHS-induced increase in pro-inflammatory macrophages. Flow cytometry
dot plots show F4/80+ SVF cells gated using PE channel against side scatter (SSC), subsets of F4/80+
cells were identified based on surface expression of CD11c and CD206 from WT and A2−/− using
unstained cells as negative control (A). Quantification of the plots shows the effect of A2 deletion on
the percentage of F4/80+ cells (B), (F4/80+CD11c+) (C), and (F4/80+CD206+) (D) of SVF, representing
total macrophage, pro-inflammatory M1-like and anti-inflammatory M2-like macrophages, respectively.
Values are means ± SEM; n = 5–6 mice/group. Adipocyte mRNA expression of TNF-α (E) and MCP-1
(F), n = 4 mice/group. * P < 0.05 when compared to ND-fed mice within the same genotype, # P < 0.05
when compared to WT on the same diet.
2.5. The HFHS Diet Increased A2 and Hypoxia-Inducible Factor (HIF)-1α Expressions in the VAT
To further assess the role of A2 on the pathological expansion, fibrosis, and inflammation of
the VAT, we ev luated A2 expressi in VAT samples (by western lot) and in isolated adip cytes
(by RT-PCR) from the HFHS and ND mice. These analyses showed a 72% elevation of A2 protein
level in the VAT (Figure 5A,B) and a 277% increase in A2 mRNA levels in isolated adi ocytes from
WT HFHS-fed mice (Figure 5C). Add tion lly, we examined HIF-1α mRNA expression in isolated
adipocytes be ause hypoxia in a ipose tissue is common under obese conditions and has been shown
to increase A2 expressi n in other cell ypes [23,24]. This analysis howe a significant upregulation
f hypoxia-inducible factor (HIF)-1α mRNA in adipocytes from WT HFHS m ce com ared to the
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ND group (Figure 5D). In line with these results, we found that differentiated 3T3-L1 cells exposed
to palmitic acid (250 µM) and high glucose (25 mM) (PA+HG) for seven days exhibited increased
expression levels of A2 protein (Figure 5E,F) and mRNA (Figure 5G), as well as HIF-1α mRNA
(Figure 5H) compared to cells maintained in control media. The A2 protein was not detected in
western blots from A2−/− mice. The levels of A1 mRNA in isolated adipocytes (Supplementary
Figure S3) were not altered by A2 deletion.
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Figure 5. HFHS increases A2 expression in VAT and adipocytes. Representative western blot (A)
and densitometry analysis (B) showing increased A2 protein levels in VAT of WT mice fed HFHS
diet (n = 4 per group). qRT-PCR showing increased A2 (C) and HIF-1α (D) mRNA levels in mature
adipocytes (AC) isolated from VAT of WT mice fed HFHS diet (n = 6–9 per group). Results are shown
as a percentage of levels in WT mice fed ND. Representative western blot (E) and densitometry analysis
(F) showing increased A2 protein levels in differentiated 3T3-L1 cell line treated with 250 µM of
palmitate (PA) and high-glucose (HG) media (25 mM) for 7 days compared to normal glucose media
(n = 4 per group). qRT-PCR showing increased A2 (G) and HIF-1α (H) mRNA levels in differentiated
3T3-L1 cells treated with PA/HG (n = 3–4 per group). Data are presented as mean ± SEM. * P < 0.05.
Int. J. Mol. Sci. 2019, 20, 1462 8 of 21
2.6. A2 Deletion Enhanced Expression of Genes Involved in Fatty Acid β-Oxidation and Preserved
Mitochondrial Density
To further explore the possible mechanisms by which A2 deletion improves metabolic
function, we analyzed effects of the A2 deletion on genes involved in fatty acid metabolism.
Consumption of HFHS diet by WT mice significantly reduced the expression of the anti-inflammatory,
insulin-sensitizing adipokine, adiponectin (Figure 6A–C), and decreased mRNA expression of
peroxisome proliferator-activated receptor gamma (PPAR-γ) coactivator 1 α (PGC1α) (Figure 6D)
and PPAR-γ (Figure 6E) in visceral adipose tissue. PGC1α and PPAR-γ are both prominent enhancers
of mitochondrial activity and fatty acid metabolism [25,26]. Moreover, expression and activity of
PGC1α are upregulated by AMPK-α activation [27,28], which we found to be increased with A2
deletion (Figure 6F,G).
The CLAMS analysis of metabolic activity revealed that the WT and A2−/− mice fed HFHS diets
were both primarily metabolizing lipids. However, the A2−/− group exhibited a higher rate of fatty
acid oxidation, a leaner phenotype, and higher energy expenditure. This observation prompted the
investigation of the effect of A2 deletion on genes involved in fatty acid metabolism. Adipocytes
from the A2−/− mice on the HFHS diet exhibited a marked increase in mRNA expression of genes
involved in fatty acid β-oxidation, oxidative phosphorylation (OXPHOS), and energy dissipation when
compared to WT mice (Figure 6H and Supplementary Figure S4). However, there were no differences
in the expression of genes involved in fatty acid uptake between WT and A2−/− mice.
Given the beneficial effects of the A2 deletion on energy expenditure and the fact that A2 is
localized to the mitochondria, we postulated that the beneficial effects of the A2 deletion under
conditions of obesity may involve preservation of the mitochondria. Sections of VAT were treated with
a non-membrane potential-dependent mitochondrial stain, MitoID-Red, to determine mitochondrial
density. Compared to WT ND mice, WT HFHS mice showed a 57% reduction in mitochondrial density
in VAT. Mitochondrial density was preserved in HFHS-fed mice lacking A2. (Figure 6I,J).
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Figure 6. A2 deletion enhanced adipocyte expression of genes involved in fatty acid metabolism
and preserved mitochondrial density. Representative western blot (A) and densitometry analysis
normalized to the loading control (β-Actin) (B) showing adiponectin protein levels in VAT,
n = 3–4/group. Adipocyte mRNA expression of adiponectin (C), n = 5–7/group. Adipocyte mRNA
expression of PGC-1α (D) and PPAR-γ (E), n = 5–8 per group. Representative western blot (F) and
densitometry analysis (G) showing ratio of p-AMPK-α to total-AMPK-α in VAT, n = 5–8/group and
mRNA expression of genes involved in fatty acid uptake, β-oxidation and oxidative phosphorylation
(OXPHOS), n = 4–6 (H). Immunofluorescence images of VAT sections stained with MitoID-Red as an
estimate of mitochondrial mass (I) with quantitation (J); scale bar = 50 µM. Values are means ± SEM;
* P < 0.05 when compared to ND-fed mice within the same genotype, # P < 0.05 when compared to WT
on the same diet.
2.7. A2 Deletion Attenuated Circulating Oxidative Species and Preserved NO Levels and Vascular Function
A2 deletion markedly attenuated HFHS-induced oxidative stress, as demonstrated by lower
plasma lipid peroxide levels compared to the WT HFHS mice (Figure 7A). An optimal level of plasma
NO has been proposed to be protective of endothelial and adipocyte function (24). Our analysis
confirmed significantly lower plasma NO levels in WT mice on HFHS versus normal diet. This effect
was blunted by A2 deletion (Figure 7B).
To determine the effect of excess nutrients and metabolic abnormalities on vascular function,
we tested the vasodilation capacity of aortas in response to the endothelial-dependent vasodilator
acetylcholine (ACh) and the endothelial-independent vasodilator sodium nitroprusside (SNP). Aortas
from WT mice fed the HFHS diet exhibited reduced maximal vasorelaxation responses to ACh
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compared to the WT ND mice. Aortas from A2−/− mice on HFHS diet showed maximal vasorelaxation
responses similar to that of ND groups (Figure 7C). To confirm that the diet-induced vasorelaxant
responses we observed were indeed endothelial-dependent, we tested the vasorelaxant responses of
the aortas to the NO donor SNP. Our results showed similar responses across all groups (Figure 7D).
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Figure 7. A2 deletion limited HFHS-induced oxidative stress, preserved NO levels and
endothelium-dependent vasorelaxation to acetylcholine (ACh). Lipid peroxides are expressed as
micromolar of malondialdehyde (MDA) (A), n = 5–9 mice/group, and plasma NO is expressed as
picomoles of nitrite (B), n = 5–9 mice/group. Effects of A2 deletion on endothelium-dependent
vasorelaxation to acetylcholine (ACh) (C), n = 7–10 mice per group, and sodium nitroprusside (SNP)
(D), n = 4–5 mice per group. Values are mean ± SEM. * P < 0.05 when compared to ND-fed mice within
the same genotype, # P < 0.05 when compared to WT on the same diet.
2.8. Arginase 1 Deletion Preserved Vascular Function in HFHS Fed Mice Without Affecting the Gain in
Body Weight
A1 heterozygous knockout (A1+/−) mice fed HFHS diet did not show any differences in gain
of body weight (Figure 8A) or VAT weight (Figure 8B) compared to WT mice on the same diet.
Interestin ly, the global hete ozygous dele ion of arginase 1 (A1+/−) resulted n a pronounced aortic
vasorelaxation with a mark d increase in sensitivity to ACh (reduction in the EC50) as compared to
re ponses of aorta from WT HFHS mice (Figure 8C).
2.9. Arginase Inhibition Prevented Vascular Endothelial Dysfunction Induced by Conditioned Medium (CM)
from VAT of WT HFHS Mice
We were particularly interested in the effects of diet on endothelial cell function. Mouse aortic
endothelial cells (MAEC) exposed to CM from VAT of WT HFHS mice (24 h) showed increased mRNA
expression of A1 and A2 (Figure 9A,B) and reduced levels of NO (Figure 9C), compared to MAEC
exposed to CM from WT ND mice. Aortic rings incubated with CM from WT HFHS mice for 24 h
exhibited marked impairment of the endothelial-dependent vasorelaxant response to acetylcholine
(ACh) (Figure 9D). Pretreatment with the arginase inhibitor ABH (100 µM) preserved NO levels and
vasorelaxant responses to ACh (Figure 9C,D). This indicates the key role of arginase in obesity-induced
endothelial dysfunction.
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Figure 8. A1 deletion enhanced endothelium-dependent vasorelaxation with no effect on the gain
of body and VAT weight. Effect of WT and A1 heterozygous deleted (A1+/−) mice challenged with
HFHS diet on gain in body weight (A), VAT weights (B), and endothelium-dependent vasorelaxation
to acetylcholine (ACh) (C). EC50: half maximal effective concentration for the ACh. Values are
mean ± SEM, n = 4–6 mice/group. * P < 0.05 when compared to WT HFHS.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 12 of 22 
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Figure 9. Vascular endothelial dysfunction induced by conditioned medium (CM) from VAT
of WT-HFHS mice involves arginase upregulation. Conditioned media (CM) was prepared by
incubating 50 mg VAT from either WT-ND or WT-HFHS mice for 24 h in M199 media. Presented
are mRNA expression of A1 (A), A2 (B), and NO production (C) in MAEC. Additionally presented
are endothelial-dependent vasorelaxant responses to acetylcholine in aortic rings from WT-ND mice
treated for 24 h with CM from VAT of WT-ND and WT-HFHS mice in the presence/absence of ABH
(100 µM) (D). Values are mean± SEM. * P < 0.05 vs. WT-ND CM, # P < 0.05 vs. WT-HFHS CM (n = 4–5).
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3. Discussion
Visceral (central) obesity is of particular importance as it directly correlates with metabolic and
cardiovascular pathologies [1,2]. Our study found that A2 deletion ameliorated the diet-induced
increase in body weight, whole-body adiposity, VAT weight, adipocyte hypertrophy, and insulin
resistance. These effects were associated with decreases in adipose tissue inflammation, enhanced
expression of genes involved in fatty acid metabolism and improved metabolic function. A previous
study showed that mice fed high fat diet exhibited an increase in A2 expression in several tissues,
including perivascular adipose tissue [29]. Treatment of mice on a high fat diet with an arginase
inhibitor Nω-hydroxy-nor-L-arginine has been shown to prevent their gain of body and adipose tissue
weight [30]. However, other obesity studies in mice lacking A2 only reported a trend toward less
body weight gain compared to WT mice [16,31]. Reasons for this discrepancy are not clear. The age
of mice when the diet begins and the duration of diet may affect the results. These studies, however,
showed favorable outcomes in terms of insulin resistance and liver steatosis in A2−/− mice, which
are in line with our data. We found that A2−/− mice on the HFHS diet had lower fasting blood
glucose and postprandial serum insulin levels and less fat deposition in liver sections than WT mice
on that diet. However, we did not observe an effect of A2 deletion on preadipocyte differentiation
in vitro. This indicates that the leaner phenotype observed in A2−/− mice may not be due to impaired
adipocyte differentiation. In contrast, a recent study reported increased macrophage inflammation and
hepatic steatosis in A2−/− mice. The results may be confounded by a difference between the starting
baseline weight of WT and A2−/− mice [21].
A2 deletion contributes to an improved metabolic phenotype as shown by our metabolic cage
studies in which A2−/− mice on HFHS exhibited higher VO2, VCO2, energy expenditure and fatty
acid oxidation rates compared to WT mice. Previous clinical and experimental studies have shown
that obesity correlates with decreased energy expenditure, which leads to a net positive energy
balance [32,33].
Obesity is characterized by pathological expansion of VAT in a locally hypoxic milieu [17,34].
This leads to immune cell infiltration, inflammation and adipose tissue fibrosis in both humans
and rodents [34–36]. Fibrosis results in a rigid extracellular structure and mechanical stress on
adipocytes, restraining their expansion [37]. In response to this stress, adipocytes release more
inflammatory cytokines and chemokines, such as TNF-α and MCP-1, and less anti-inflammatory
adipokines, like adiponectin [7,8]. The role of arginase in fibrosis is mediated in part via its conversion
of L-arginine into L-ornithine, which is subsequently metabolized to L-proline, the major constituent
of collagen [12]. In this study, our analyses of VAT showed that A2 deletion blunted the HFHS
diet-induced collagen fiber deposition, prevented the infiltration of pro-inflammatory M1 macrophage
and reduced adipocyte expression of TNF-α and MCP-1. Others have reported that deletion of A2
dampens the inflammatory macrophage response in HFHS fed mice as shown by a reduction in the
inflammatory macrophages phenotype (M1) and expression of pro-inflammatory cytokines in adipose
tissue [16]. Our study also sought to determine the effect of A2 deletion on the anti-inflammatory
macrophage phenotype M2. Levels of the M2 macrophages were not altered by the HFHS diet; however,
A2−/− mice on ND showed significantly higher M2 levels compared to other groups. Initiation of M1
recruitment and/or polarization is well characterized and suggested to be caused by TNF-α secretion
from hypertrophied adipocytes [38]. However, the initiator of the anti-inflammatory/resolving M2
macrophage recruitment/polarization in adipose tissues is not fully understood. Previous studies
have shown increased as well as decreased M2 macrophage levels in obese adipose tissue [39,40].
The exact mechanism of obesity-induced A2 upregulation in VAT/adipocytes is not clearly
understood. We hypothesized that hypoxic milieu in adipose tissue might play a critical role.
In adipocytes, HIF-1α is considered the main mediator of the hypoxic response and involved in
the pathophysiological consequences of adipocyte dysfunction during obesity [23]. It is reported that
hypoxia also induces A2 upregulation in pulmonary artery smooth muscle [24]. In our study, the high
fat diet increased the expression of HIF-1α and A2 in adipocytes from WT mice.
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Reduced energy expenditure is due in part to downregulation of genes involved in fatty acid
catabolism and oxidation [41]. While reduced fatty acid oxidation is considered to be a risk factor for
obesity [42], it has been suggested that induction of energy expenditure during fatty acid oxidation
in white adipose tissue reduces adiposity and promotes a lean phenotype [10]. Increased fatty acid
β-oxidation in adipose tissue has been shown to reduce adiposity, inflammatory cell infiltration and
improve insulin sensitivity [43–45]. A prior study showed mice lacking A2 were protected against
high fat diet-induced steatohepatitis and that hepatic levels of active AMPK-α were higher than in
WT mice [31]. Our study showed for the first time that A2 deletion increases activation of AMPK-α in
adipose tissue. Active AMPK-α has been shown to induce expression and activity of PGC-1α [28], which
coordinates the actions of PPAR-γ and PPAR-α to increase mitochondrial biogenesis and function,
including expression of enzymes involved in mitochondrial fatty acid β-oxidation and oxidative
phosphorylation [5,46]. Clinical and experimental studies have revealed decreased PGC-1α expression
in fat depots of obese subjects [47]. PPAR-γ is considered the major positive regulator of adiponectin
expression in adipose tissue [48]. Consistent with the protective effects of the A2 deletion in preserving
PGC-1α and PPAR-γ expression in adipocytes, HFHS-fed A2−/− mice showed significant preservation
of adipocyte mitochondria as compared with the WT mice. Interestingly, our current findings also
show that A2 deletion ameliorates the reduction of adiponectin expression, which is in line with a
previous study [31]. It also improves adipocyte metabolic function under high fat diet challenge.
Moreover, adiponectin has been shown to activate AMPK-α [49].
In patients with type 2 diabetes, obesity closely coexists with endothelial dysfunction [50], a
hallmark of all cardiovascular diseases [51]. Several lines of evidence suggested a critical role
of oxidative stress and increased lipid peroxidation in the link between obesity and vascular
disorders [52,53]. Plasma levels of malondialdehyde (MDA) are a frequently used indicator of lipid
peroxidation and have been shown to positively correlate with body mass index [54]. We found MDA
elevated in WT mice on the HFHS diet, but not in mice lacking A2. Additionally, our group and
others have shown that increased arginase expression/activity and a concomitant reduction in NO
bioavailability are involved in obesity and diabetes-induced vascular dysfunction [17,55]. In this study,
we found that A2 deletion blunted the HFHS-induced increase in plasma MDA and reduction in plasma
NO levels. In addition, deletion of A2 prevented HFHS-induced vascular endothelial dysfunction.
However, this effect was more pronounced in mice lacking A1, even though these mice had a similar
weight gain as WT HFHS mice. This suggests a differential involvement of the two arginase isoforms in
metabolic and vascular dysfunction associated with obesity as well as underscoring the critical role of
A1 in vascular endothelial function which is in agreement with our recent reports [17,18]. It is possible
that A2 deletion in HFHS-fed mice could indirectly improve VAT metabolic function by increasing
vascular endothelial function and blood flow, rather than by direct effects on adipose tissue. However,
it is unlikely, since vascular endothelial function for A1+/− mice on that diet was markedly better and
their gain in body/VAT weight was not affected.
We were also interested in determining the direct effects of factors released by VAT on endothelial
cells and aortic explants without interference from systemic factors. We found that conditioned
media from VAT of WT-HFHS mice increased expression of A1 and A2 in isolated endothelial cells in
culture. It also reduced endothelial NO production and depressed endothelial-dependent vasorelaxant
responses in isolated vessels. Both actions were prevented by arginase inhibition.
Collectively, our current study shows that deletion of A2 in mice alleviates HFHS-induced obesity
and limits the associated metabolic dysfunctions. Our study demonstrates for the first time the
beneficial effect of A2 deletion on energy expenditure and lipid metabolism. This may be attributed
to increased AMPK-α activity, improved adipocyte metabolic function, suppression of adipose tissue
inflammation and fibrosis. Additionally, there are a concomitant preservation of systemic NO levels
and a normalized oxidative status, which can limit obesity-induced vascular dysfunction. Based on
our findings, it appears important to examine the specific role of A2 in adipocytes and macrophages.
Previous studies have linked A2 expression to insulin resistance, atherosclerosis and hepatic steatosis,
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which were attributed to an enhanced macrophage inflammatory response [16,31]. It has been shown
that deletion of metabolically relevant genes, either in adipocytes or macrophages, yield similar
metabolic phenotypes [56,57]. This study raises important questions: Are hypoxic conditions and
elevated HIF-1α levels during obesity involved in A2 upregulation? Does A2 deletion reduce HIF-1α
levels and thus mitigate adipocyte dysfunction? What is the interplay between endothelial cells and
adipocyte dysfunction? And which one precedes the other? Also, what is the impact of A2 deletion in
other tissues involved in metabolism, including muscle, liver and brown adipose tissue? Although the
expression of UCP-1 in VAT is low [58], A2 deletion showed a trend towards increased expression of
this browning/beiging protein. Thus, the effect of A2 deletion on browning of adipose tissue warrant
further investigation.
4. Materials and Methods
4.1. Animal Studies
All animal procedures were performed following the National Institutes of Health Guide for
the Care and Use of Laboratory Animals and were approved on 05/26/2016 as protocol number
2010-0230 by the Institutional Animal Care and Use Committee at Augusta University. A2-deficient
(A2−/−), A1 heterozygous-deficient (A1+/−), and wild type (WT) male mice bred from a C57BL/6J
background were used in this study. The development, breeding, and genotyping of these mice
have been previously described [59]. All animals developed to term, grew normally after birth and
were fed a normal chow diet (ND) (calorie percentage: 18% fat, 24% protein, 58% carbohydrate with
approximately 5% from sucrose, Harlan, Madison, WI, USA) or a high-fat high-sucrose (HFHS) diet
(calorie percentage: 59% fat, 15% protein, 26% carbohydrate with 20% from sucrose, F#1850, BioServe,
Frenchtown, NJ, USA). The diets were started four weeks after birth and continued for 16 weeks to
experimentally mimic the conditions of metabolic syndrome [60,61]. Animals were kept at ambient
temperature on a 12:12 h light/dark cycle and were fed ad libitum.
4.2. Body Weight, Body Composition, Fasting Blood Glucose, and Serum Insulin
Body weight was measured weekly throughout the experiment, and after 14 weeks on the diet,
body composition was determined using a Bruker minispec LF90 TD-Nuclear magnetic resonance
(NMR) analyzer. At the end of the study, the mice were fasted overnight and their fasting blood glucose
(FBG) was measured using an AlphaTRAK glucometer. After determining their FBG, the mice were
allowed access to food for 2 h [17]. Their post-prandial serum insulin levels were then determined
using an Ultra-Sensitive Mouse Insulin ELISA Kit (Crystal Chem. USA, Downers Grove, IL, USA).
4.3. Indirect Calorimetry
After 14 weeks on the diets, an indirect respiration calorimetry system (CLAMS) was used to
determine the metabolic rate and substrate utilization of the mice (Columbus Instruments, Columbus,
OH, USA). Animals were maintained at 24 ◦C and a 12 h light/dark cycle. Food intake, respiratory
exchange ratio (ratio of VCO2 to VO2), metabolic energy expenditure (heat produced), and locomotor
activity were determined after a 24 h acclimatization period. The data were averaged over 48 h as
previously described [62]. Rate of fatty acid oxidation was calculated according to the following
formula: ([1.695 × VO2] − [1.701 × VCO2]) × 9/1000 [63].
4.4. Tissue Harvest
Mice were given an intraperitoneal (IP) injection of a ketamine/xylazine cocktail and
exsanguinated. The blood, epididymal visceral adipose tissue (VAT), and liver were collected from
each animal. A portion of the liver was fixed in 4% paraformaldehyde (PFA) for histological studies.
The VAT was weighed and a portion was fixed for Masson-trichrome stain of collagen levels (fibrosis)
and determination of adipocyte size using ImageJ software (NIH-Fiji, Bethesda, MD, USA) and
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Adiposoft plug-in (University of Navarra, Pamplona, Spain). Sections of the VAT were also used
for immunofluorescence staining of the mitochondrial marker (MITO-ID® Red, kit ENZ-51007, Enzo
Life Sciences, Farmingdale, NY, USA) to assess mitochondrial density. Another portion of the VAT
(500–700 mg) was fractionated using collagenase I (Worthington Biochemical Corporation, Lakewood,
NJ, USA) to isolate floating mature adipocytes from the pelleted stromal vascular fraction (SVF) [18,64].
The remaining tissues were stored at −80 ◦C for protein analysis.
4.5. Flow Cytometry Analysis
The SVF was incubated with erythrocyte lysis buffer (Sigma-Aldrich; Darmstadt, Germany) for
five minutes, washed with 1X D-PBS buffer and then centrifuged. 1 × 106 SVF cells were re-suspended
in ice-cold Flow Cytometry Staining Buffer (eBioscience, San Diego, CA, USA). A small portion of
the cells was used to determine the percentage of live cells per sample with a hemocytometer based
on trypan blue exclusion. Remaining cells were incubated in Fc Block (BD Bioscience, San Jose,
CA, USA) for five minutes at 4 ◦C. Then, they were incubated with the following fluorochrome
conjugated antibodies: phycoerythrin (PE)-conjugated anti-F4/80 (Cedarlane, Burlington, NC, USA),
APC-conjugated anti-CD11c (BD Pharmingen™, San Diego, CA, USA), fluorescein isothiocyanate
(FITC)–conjugated anti-CD206 (BD Pharmingen™) for 40 min. After incubation, the cell suspensions
were washed and re-suspended in the flow cytometry staining buffer. The percentage of the total, M1, or
M2 macrophages in the SVF were identified as being either F4/80+, F4/80+CD11c+, or F4/80+CD206+
double positive populations, respectively. Samples were acquired in MACSQuant® Analyzer 10 and
analyzed using MACSQuantify™ Software (Miltenyi Biotec Inc., Auburn, CA, USA).
4.6. Quantitative Reverse Transcription-PCR (Q-PCR)
Mature adipocytes isolated from the VAT were washed twice with PBS and the total RNA was
isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
guidelines. Reverse transcription was performed using M-MLV reverse transcriptase (Invitrogen)
to create cDNA. A StepONe Plus thermocycler (Applied Biosystems, Foster City, CA, USA) was
used to amplify the cDNA with TaqMan Gene Expression assays for either A2 or Hypoxia-Inducible
Factor (HIF)-1α (Applied Biosystems) or SYBR Green Dye (Applied Biosystems™) and specific primers
for TNF-α, MCP-1, A1, Adiponectin, PGC-1α, PPAR-γ, CD 36, LPL, PPAR-α, PPAR-δ, MCAD, LCAD,
ACOX-1, UCP-2, COX-8b, Ndufa1, Atp5b, or UCP-1. The primer sequences used are shown in Table 1.
Relative gene expression was calculated using the 2−∆∆Ct method, the change in cycle threshold,
determined by the initial increase in fluorescence above background, and normalized to hypoxanthine
phosphoribosyl transferase (HPRT) expression as previously described [65,66]. PCR products were
separated by electrophoresis on 1% agarose gels stained with ethidium bromide.
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Table 1. Sequence of primers used for RT-PCR experiments.
Mouse Gene Symbol Gene Name Forward Reverse
TNF-α Tumor necrosis factor alpha GCACCACCATCAAGGACTCA TCGAGGCTCCAGTGAATTCG
MCP-1 Monocyte chemoattractant protein 1 GGCTCAGCCAGATGCAGTTAA CCTACTCATTGGGATCATCTTGCT
A 1 Arginase 1 TTGGGTGGATGCTCACACTG TTGCCCATGCAGATTCCC
Adiponectin Adiponectin AAGGACAAGGCCGTTCTCT TATGGGTAGTTGCAGTCAGTTGG
PGC-1α Peroxisome proliferator-activatedreceptor gamma coactivator 1-alpha AACCACACCCACAGGATCAGA TCTTCGCTTTATTGCTCCATGA
PPAR-
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Peroxisome proliferator-activated
receptor gamma CAAGAATACCAAAGTGCGATCAA GAGCTGGGTCTTTTCAGAATAATAAG
CD36 Cluster of differentiation 36 TTG CCTATACTG G CTAAATG GA CTTGTGTTTTGAACATTTCTGCTT
LPL Lipoprotein lipase CTGCT GCGTAGCAGGAAGT GCTGGAAAGTGCCTCCATTG
PPAR-α Peroxisome Proliferator ActivatedReceptor alpha GCGTACGGCAATGGCTTTAT ACAGAACGGCTTCCTCAGGTT
PPAR-δ Peroxisome Proliferator ActivatedReceptor Delta CCTCGGGCTTCCACTACG CACTTGTTGCGGTTCTTCTTC
Ucp-2 uncoupling protein 2 GCCCGGGCTGGTGGTGGTC CCCCGAAGGCAGAAGTGAAGTGG
Acox-1 Acyl-CoA oxidase 1 GCCAAGGCGACCTGAGTGAGC ACCGCAAGCCATCCGACATTC
MCAD Medium-chain acyl-CoAdehydrogenase AACACTTACTATGCCTCGATTGCA CCATAGCCTCCGAAAATCTGAA
LCAD Long-chain acyl-CoAdehydrogenase TGGCAAAATACTGGGCATC TCTTGCGATCAGCTCTTTCA
Ndufa1 NADH:Ubiquinone OxidoreductaseSubunit A1 ACATCCACAAATTCA CAACGG AGCGATTGACTCCAGAGATACG
COX-8b Cytochrome c oxidase subunit 8B GAACCATGAAGCCAACGACT GCGAAGTTCACAGTGGTTCC
Atp5b ATP Synthase F1 Subunit Beta CATTGGTGATGGTATTGCGC TCCCAAACACGACAACTCC
UCP- Uncoupling protein 1 TCTTCTCAGCCGGAGTTTCAGCTT ACCTTGGATCTGAAGGCGGACTTT
HPRT HypoxanthineP sphoribosyltransferase 1 G AAGACTTGCTCGAGATGTCAT CACACAGAGGGCCACAATGT
4.7. Adipose Tissue Western Blot
Visceral adipose tissue was collected and protein lysates were centrifuged at 100,000× g to remove
neutral lipids. Then, 20 µg of the lysates were subjected to electrophoresis on SDS-polyacrylamide gels
and transferred to nitrocellulose membranes where they were blocked in 5% non-fat milk (Bio-Rad,
Hercules, CA, USA) and then incubated overnight at 4 ◦C with primary antibodies prepared in
2% bovine serum albumin. A2 (Santa Cruz Biotechnology cat. #Sc-20151, Dallas, TX, USA; 1:250),
adiponectin (Santa Cruz Biotechnology cat. # Sc-136131, Dallas, TX, USA; 1:250), p-AMPK-α (Cell
Signaling Technology cat. #2535 Danvers, MA, USA; 1:500), total AMPK-α (Cell Signaling Technology
cat. #2603, Danvers, MA, USA; 1:500) and β-actin (Sigma-Aldrich cat. #A1978, 1:5000). The following
day, membranes were washed three times in TBS-T (Tris-buffered saline with 0.5% Tween-20) and
then incubated with the corresponding horseradish peroxidase-conjugated secondary antibodies
(GE Healthcare, Piscataway, NJ, USA) for one hour at room temperature (1:2500). Signals were
detected using an enhanced chemiluminescence system (GE Healthcare Bio-Science Corp., Piscataway,
NJ, USA) and quantified by densitometry using ImageJ software and normalized to the loading control.
4.8. Preadipocyte Isolation and Adipogenic Differentiation In Vitro
The epididymal VAT was dissected from WT and A2−/− mice and digested to isolate SVF
pellets as described earlier. Cells were re-suspended, cultured, and grown in preadipocyte medium
(Cell Applications, San Diego, CA, USA) [67], cells were resuspended, cultured and grown in
preadipocyte medium (Cell Applications). Cells were passaged twice, and upon confluency,
differentiated using adipocyte differentiation media (Cell Applications) for 2–3 days; then, the
media was changed to adipocyte maintenance media (Cell Applications). After eight days of the
differentiation process, cells were either collected in RIPA lysis buffer for protein quantification
using Bio-Rad protein assay kit (Lowry method) or washed in PBS, fixed in 4% PFA (Thermofisher,
Waltham, MA, USA) and stained with Oil Red O (Sigma) in 2-propanol. The stain was then extracted
using 2-propanol and the color intensity was measured spectrophotometrically at 510 nm. The data
is represented as OD units per mg protein [64]. The murine 3T3-L1 preadipocytes cell line was
obtained from the ATCC, cultured in preadipocyte medium (ZenBio, Research Triangle Park, NC,
USA) and subsequently differentiated in adipocyte differentiation medium (ZenBio) according to the
manufacturer instructions. After seven days of differentiation, cells were exposed to the saturated
free fatty acid, palmitate (16:0) (250 µM) (Sigma), and high glucose (25 mM) (PA/HG), a condition
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that mimics obesity in vitro or control media (no palmitate and 5mM of glucose) [68] or control media
(no palmitate and 5mM of glucose). Cells were collected in TRIzol for PCR or in RIPA buffer for
protein analyses.
4.9. Determination of Plasma Lipid Peroxide Levels and NO
Plasma levels of lipid peroxides were measured as an indicator of reactive oxygen species by
assessing levels of thiobarbituric acid reactive substances spectrophotometrically at 532 and expressed
as micromolar of malondialdehyde (MDA) [69]. NO production was determined using a Sievers 280i
NO Analyzer (Boulder, CO, USA) and nitrite (NO2−) levels, the stable breakdown product of NO were
quantified by a chemiluminescence detector [17].
4.10. Vascular Function
Vascular function was measured as previously described [17]. The aortas were rapidly excised
and placed in cold Krebs buffer (pH 7.4). After removal of the perivascular fat, 2 mm rings were
sectioned from thoracic aorta. Rings were then mounted and equilibrated in myograph baths (Danish
MyoTechnology, Gainesville, FL, USA) filled with Krebs solution at 37 ◦C under a resting tension of
5.0 mN and perfused with 95% O2 and 5% CO2. A Power Lab system (AD Instruments, Colorado
Springs, CO, USA) was used to measure the isometric force. The contraction in response to KCl
(8 mmol/L) was assessed. After, the cumulative concentration-response curves to acetylcholine
(ACh, an endothelium-dependent vasodilator, 0.001–10 µmol/L) or sodium nitroprusside (SNP, an
endothelium-independent vasodilator, 0.0001–1 µmol/L) were obtained after pre-contracting the
aortas with phenylephrine (1 µmol/L).
4.11. Conditioned Media (CM) Preparation from VAT and Endothelial Cell Treatment
To study the specific role of central obesity on endothelial function, conditioned media (CM)
was prepared by incubating 50 mg of VAT from either WT ND or WT HFHS mice for 24 h in M199
media [70,71]. Mouse aortic endothelial cells (MAEC) were cultured, passaged as described [18]
and exposed to CM for 24 h. In some of the experiments, cells were pretreated with the arginase
inhibitor, 2-(S)-amino- 6-boronohexanoic acid (ABH), kindly provided by Corridor Pharmaceuticals,
Inc. (Baltimore, MD, USA). In these experiments, the collected supernatant was used to measure
NO levels and cells were collected for mRNA expression analysis of A1 and A2 using TaqMan Gene
Expression assays. Additionally, aortic rings from WT ND mice were incubated with CM for 24 h
ex vivo in the presence or absence of ABH, as previously described in [17] and vascular function
was assessed.
4.12. Statistical Analysis
Results are expressed as mean ± SEM. Statistical analyses were tested by GraphPad Prism 7
(GraphPad Software Inc., La Jolla, CA, USA) using the unpaired Student’s two-tailed t-test or the
two-way ANOVA followed by Tukey’s post hoc tests as appropriate. The effect of dietary intervention
on body weight and vascular function were analyzed by two way repeated-measures ANOVA. Values
of P < 0.05 were considered significant.
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s1. Supplementary Figures S1–S4 and their legends are presented separately.
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